Universe Pharmaceuticals Inc (UPC)vsZoetis Inc (ZTS)
UPC
Universe Pharmaceuticals Inc
$2.25
-1.43%
HEALTHCARE · Cap: $1.28M
ZTS
Zoetis Inc
$116.71
+0.67%
HEALTHCARE · Cap: $51.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 52911% more annual revenue ($9.47B vs $17.86M). ZTS leads profitability with a 28.2% profit margin vs -20.6%. ZTS earns a higher WallStSmart Score of 64/100 (C+).
UPC
Avoid29
out of 100
Grade: F
ZTS
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for UPC.
Margin of Safety
-29.1%
Fair Value
$99.69
Current Price
$116.71
$17.02 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Every $100 of equity generates 66 in profit
Strong operational efficiency at 34.7%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Areas to Watch
Smaller company, higher risk/reward
ROE of -7.2% — below average capital efficiency
Revenue declined 14.1%
Earnings declined 82.0%
Expensive relative to growth rate
Trading at 14.9x book value
3.0% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : UPC
The strongest argument for UPC centers on Price/Book, Altman Z-Score, Debt/Equity.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.2% and operating margin at 34.7%.
Bear Case : UPC
The primary concerns for UPC are Market Cap, Return on Equity, Revenue Growth.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.85 is elevated, increasing financial risk.
Key Dynamics to Monitor
UPC profiles as a turnaround stock while ZTS is a value play — different risk/reward profiles.
UPC carries more volatility with a beta of 1.57 — expect wider price swings.
ZTS is growing revenue faster at 3.0% — sustainability is the question.
ZTS generates stronger free cash flow (732M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (64/100 vs 29/100), backed by strong 28.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Universe Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Universe Pharmaceuticals INC, a pharmaceutical company, is engaged in the manufacture, marketing, distribution and sale of products derived from traditional Chinese medicine in China.
Visit Website →Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?